ライフサイエンスコーパス: liver cyst

1 e (ERK) 1/2 pathway stimulates the growth of liver cysts.

2 cystic area and a nonsignificant decrease in liver cysts.

3 form cyst formation and presence of adjacent liver cysts.

4 onophosphate (cAMP) in cholangiocytes lining liver cysts.

5 y disease that exhibit cholangiocyte-derived liver cysts.

6 ence, mutant hepatocystin is undetectable in liver cysts.

7 cm for solid nodules and 14 cm for solitary liver cysts.

8 brosis and portal hypertension as well as of liver cysts.

9 ant, resulting in a significant reduction in liver cysts.

10 cysts, limited kidney insufficiency, and few liver cysts.

11 1 %) patients underwent only fenestration of liver cysts.

12 cysts (69.2% vs. 15.4%), but not one or more liver cyst (11.5% vs. 7.7%).

13 th non-enlarged cystic kidneys and few or no liver cysts; 8 subjects reached end-stage kidney disease

14 With age, cholangiocytes lining liver cysts acquire features of mesenchymal cells contri

15 predisposing to the combination of renal and liver cysts (AD-PKD1 and AD-PKD2) and mutations in a thi

16 Patients typically have hypertension and liver cysts, and 9% to 14% develop intracranial aneurysm

17 This disease is characterized by renal and liver cysts, and cardiovascular extrarenal manifestation

18 imary biliary cirrhosis, cholangiocarcinoma, liver cysts, and in the progression of biliary fibrosis

19 Cholangiocyte cilia in liver cysts are structurally abnormal.

20 Sorafenib caused an unexpected increase in liver cyst area, cell proliferation (Ki67), and expressi

21 nhibitor rapamycin significantly reduced the liver cyst area, liver/body weight ratio, pericystic mic

22 sease (ARPKD), develop cholangiocyte-derived liver cysts associated with increased intracellular aden

23 ADPKD liver cyst cell cultures also released IL-8 and vascular

24 kidney disease (ADPKD) involves formation of liver cysts derived from intrahepatic bile ducts.

25 ACY-1215 administered to PCK rats diminished liver cyst development and fibrosis.

26 GFR-2 inhibitor SU5416 significantly reduced liver cyst development, liver/body weight ratio, and exp

27 antly at increased risk of having any kidney/liver cyst diagnosis (Odds Ratio 2.42, 95% confidence in

28 ine factors to direct errant growth of ADPKD liver cyst epithelia.

29 Liver cyst epithelial cells (LCECs) express vascular end

30 conditions, electron microscopy of the ADPKD liver cyst epithelium revealed morphological features si

31 A novel mechanism of liver cyst expansion in PCLD involves microRNA regulator

32 y provide therapeutic targets for inhibiting liver cyst expansion.

33 immunosorbent assay analysis of human ADPKD liver cyst fluid detected epithelial neutrophil attracta

34 ential growth factors present in human ADPKD liver cyst fluid.

35 he changes in signaling pathways involved in liver cyst formation and progression, and their impact o

36 kd2, and to provide evidence that kidney and liver cyst formation associated with Pkd2 deficiency occ

37 This signaling axis is conserved in liver cysts from patients with either autosomal dominant

38 We investigated the effects of VEGF on liver cyst growth and autocrine VEGF signaling in mice w

39 atment of liver and kidney cancers, inhibits liver cyst growth in PC2-defective mice, we treated PC2

40 hat there are common cellular mechanisms for liver cyst growth regardless of the underlying genetic c

41 thelial growth factor (VEGF), which promotes liver cyst growth via autocrine and paracrine mechanisms

42 Although the minimally invasive treatment of liver cysts has been reported, the laparoscopic approach

43 gle patient suffering from multiple infected liver cysts has provided the opportunity to observe and

44 In light of the focal nature of liver cysts in ADPLD, the apparent loss-of-function muta

45 ro and in vivo, as shown by the reduction of liver cysts in mice treated with combined octreotide and

46 /2-VEGF signaling pathway promotes growth of liver cysts in mice.

47 acrine VEGF signaling promotes the growth of liver cysts in Pkd2KO mice.

48 multiple extrarenal complications, including liver cysts, intracranial aneurysms, and cardiac valvula

49 Indications were solitary giant liver cysts (n = 16), polycystic liver disease (n = 9),

50 , >10 cysts), with greater median kidney and liver cyst numbers than controls.

51 When given to epithelial cells isolated from liver cysts of Pkd2cKO mice (Pkd2cKO-cells), sorafenib p

52 polycystic liver disease (PCLD) consists of liver cysts that are radiologically and pathologically i

53 mutations in a third gene yielding isolated liver cysts (the polycystic liver disease gene).

54 lesions were renal cysts, liver hemangiomas, liver cysts, thyroid nodules, and uterine leiomyomas.

55 Liver cyst tissue and normal hepatic tissue samples from

56 Somatostatin analogues and sirolimus reduce liver cyst volume in PCLD patients.

57 ht-adjusted total kidney volume (htTKV), and liver cyst volume.

58 e severe renal disease, but women had larger liver cyst volumes.

59 isolated intrahepatic bile ducts (IBDUs) and liver cysts was analyzed by confocal and immunoelectron

60 vo effects of Trpv4 activation on kidney and liver cysts was analyzed in PCK rats.

61 Liver cysts were common (71%), with enlarged livers (>2L

62 All giant solitary liver cysts were considered for laparoscopy.

63 All solitary liver cysts were fenestrated in less than 1 hour.